Pfizer-BioNTech vaccine induces the production of cross-reactive antibodies against Trypanosoma cruzi proteins: A preliminary study.

López-Monteon AracelyAreli Eunice Balderas-CaballeroJorge Alberto Domínguez-GuillénHéctor Romero-RamírezShantal Lizbeth Baltierra-UribeRamos-Ligonio Angel

Published in: Tropical medicine & international health : TM & IH (2023)

The data suggest that people convalescing from coronavirus disease 2019 and those who received the Pfizer-BioNTech vaccine exhibit cross-reactive antibodies against T. cruzi antigens in ELISA assays.

Keyphrases

trypanosoma cruzi
coronavirus disease
electronic health record
high throughput
big data
respiratory syndrome coronavirus
machine learning
immune response
monoclonal antibody
artificial intelligence